ALK-Abelló A/S (CPH:ALK.B)
Denmark · Delayed Price · Currency is DKK 201.20
+1.00 (0.50%)
Aug 29, 2025, 4:59 PM CET
ALK-Abelló Revenue
ALK-Abelló had revenue of 1.53B DKK in the quarter ending June 30, 2025, with 11.14% growth. This brings the company's revenue in the last twelve months to 5.86B, up 13.15% year-over-year. In the year 2024, ALK-Abelló had annual revenue of 5.54B with 14.78% growth.
Revenue (ttm)
5.86B
Revenue Growth
+13.15%
P/S Ratio
7.59
Revenue / Employee
2.11M
Employees
2,753
Market Cap
44.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.54B | 713.00M | 14.78% |
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | 3.49B | 217.00M | 6.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 311.94B |
| Coloplast | 27.87B |
| Genmab | 23.16B |
| Demant | 22.59B |
| H. Lundbeck | 23.52B |
| Zealand Pharma | 9.11B |
| Ambu A/S | 5.96B |
| Bavarian Nordic | 6.46B |
ALK-Abelló News
- 10 months ago - Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins - GuruFocus